EULAR 2022 Featured Industry Abstracts Save

Jack Cush, MD

May 31, 2022 5:12 pm

Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.

Abbvie

AbbVie sponsored abstracts that will be presented include 3 oral presentations, 3 abstracts selected for poster tours and 25 posters. This includes a dominant number of new trials with upadacitinib and several with the IL-23 inhibitor Risankizumab and adalimumab.

Drug	Abstract #	Presentation Title
Upadacitinib	OP0016	Efficacy and Safety of Upadacitinib in Patients with Active Non-Radiographic Axial Spondyloarthritis: A Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial
	OP0149	Radiographic Progression from Non-Radiographic to Radiographic Axial Spondyloarthritis: Results from a 5-Year Multi-Country Prospective Observational Study
	POS0541	Predictors of Remission in Rheumatoid Arthritis Patients Treated with Upadacitinib or Adalimumab in the SELECT-COMPARE Phase 3 Study: Clinical Status at Week 12, but not Standard Laboratory Measures, Provides the Best Current Predictor of Remission at Week 26

Aurinia

Aurinia announced that multiple studies of voclosporin will be presented at the EULAR 2022 – these focus on renal outcomes in SLE.

Drug	Abstract #	Presentation Title
Voclosporin	POS0186	Voclosporin for Lupus Nephritis: Results of the Two-year AURORA 2 Continuation Study
	OP0285	Voclosporin is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

UCB

UCB will feature several new studies with the new dual IL-17 inhibitor bimekizumab being used in the treatment of psoriatic arthritis and axial spondyloarthritis.

Drug	Abstract #	Presentation Title
Bimekizumab	LB001	BE OPTIMAL - BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY,
	OP0255	BE COMPLETE - IMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY,
	OP0119	BE MOBILE 1 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY,